A Study to Evaluate the Pharmacokinetics of LY2624803 in Subjects With Hepatic Impairment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2010-11-30

Study Completion Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the impact of hepatic dysfunction on the pharmacokinetics and safety of LY2624803 and its major metabolite, LSN2797276.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

NCT04166942

Hepatic Impairment

COMPLETED PHASE1

A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment

NCT02387814

Hepatic Insufficiency

COMPLETED PHASE1

Effect of Hepatic Impairment on LDE225..

NCT01764776

Normal Hepatic Function Impaired Hepatic Function

COMPLETED PHASE1

A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment

NCT01767948

Hepatic Impairment

COMPLETED PHASE1

Evaluation of the Pharmacokinetics of Ulimorelin in Subjects With Hepatic Impairment and Healthy Subjects

NCT01405599

Digestive System Disorders

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insomnia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal hepatic function

6mg, oral, once on day 1

Group Type EXPERIMENTAL

LY2624803

Intervention Type DRUG

Administered orally

Mild hepatic impairment

6 mg, oral, once on day 1

Group Type EXPERIMENTAL

LY2624803

Intervention Type DRUG

Administered orally

Moderate hepatic impairment

6 mg, oral, once on day 1

Group Type EXPERIMENTAL

LY2624803

Intervention Type DRUG

Administered orally

Severe hepatic impairment

6 mg, oral, once on day 1

Group Type EXPERIMENTAL

LY2624803

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY2624803

Administered orally

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All Subjects

* Sexually active male and female subjects and their partners must agree to use 2 methods of contraception such as condom or occlusive cap (diaphragm or cervical/vault caps) together with spermicidal foam/gel/film/cream/suppository, from the time the subject enters the study until 3 months after the final dosing occasion, unless the male subject or partner has been sterilized (with confirmed azoospermia).
* Have a BMI between 18.5 and 35.0 kg/m2, inclusive.
* Have a body weight \>50 kg.
* Have normal sitting blood pressure and heart rate compatible with their disease state, as determined by the investigator.
* Have venous access sufficient to allow blood sampling as per the protocol.
* Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
* Have given written informed consent approved by Lilly and the Ethical Review Board governing the site.

Control Subjects

* Are males or females and with normal hepatic function, as determined by medical history and physical examination.
* Have clinical laboratory test results within normal reference range for the investigator site, or results with minor deviations not considered to be clinically significant by the investigator.

Hepatic Impaired Subjects

•Have stable hepatic impairment (alcoholic, posthepatitis, biliary cirrhosis, cryptogenic) classified as Child-Pugh class A, B, or C (mild, moderate, and severe impairment) who are considered acceptable for participation in the study by the investigator.

Exclusion Criteria

All Subjects

* Are currently enrolled in, or discontinued within the last 90 days from the last dosing occasion in a clinical trial involving an investigational drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
* Have known allergies to LY2624803 or related compounds.
* Have previously discontinued from this study or any other study investigating LY2624803.
* Have an abnormality in the 12-lead ECG that, in the opinion of the investigator, increases the risk associated with participating in the study.
* Regularly use known drugs of abuse and/or show positive findings on urinary drug screening.
* Show evidence of human immunodeficiency virus (HIV) and/or positive HIV antibodies.
* Have donated blood of more than 500 mL within the last 3 months prior to the screening visit.
* Use drugs or herbal remedies that are known inhibitors or inducers of CYP3A4 or inhibitors of CYP2D6 enzyme pathways, unless in the opinion of the sponsor and investigator the medication will not compromise safety.
* Are liver transplant subjects or have taken immunosuppressants following any organ transplant.
* Have shown signs of variceal bleeding during the last 2 weeks prior to screening.
* Show evidence of irritable bowel syndrome or chronic diarrhea.
* Have an average weekly alcohol intake that exceeds 28 units per week (males) and 21 units per week (females), and are subjects unwilling to stop alcohol consumption for the duration of the study (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).
* Are unable to swallow whole capsules.
* Are on total parenteral nutrition (TPN).
* Take anticoagulants for therapeutic use.
* Have a history of breast cancer.
* Exhibit any other condition, which, in the opinion of the investigator would preclude participation in the study.

Control Subjects

* Have any medically significant history of neurologic disease, cancer, or cardiac, respiratory, metabolic, hepatic, renal, gastrointestinal (except appendectomy), dermatological, venereal, hematological disorder or disease.
* Have creatinine clearance (CrCl) \<80 mL/min, as calculated by Cockcroft-Gault equation.
* Show evidence of significant active neuropsychiatric disease in the opinion of the investigator.
* Show evidence of hepatitis B and/or positive hepatitis B surface antigen (HBsAg).
* Show evidence of hepatitis C and/or positive hepatitis C antibody.

Mild Hepatic Impaired Subjects (Child-Pugh A)

* Show evidence of any significant active disease other than that responsible for or associated with hepatic impairment.
* Show evidence of active renal disease with creatinine clearance \<70 mL/min as calculated by Cockcroft-Gault equation.
* Have severe ascites.

Moderate and Severe Hepatic Impaired Subjects (Child-Pugh B and C)

* Show evidence of any significant active disease other than that responsible for or associated with moderate or severe hepatic impairment.
* Show evidence of hepatorenal syndrome as shown by creatinine clearance \<50 mL/min, as calculated by the Cockcroft-Gault equation.
* Have shown signs of spontaneous bacterial peritonitis within 6 months prior to dosing.
* Have severe hyponatremia.
* Have hepatic encephalopathy (grade 2 to 4 encephalopathy).
* Show signs of hepatocellular carcinoma.
* Have a portal shunt.
* Show, in the opinion of the investigator, evidence of significant active neuropsychiatric disease other than grade 1 hepatic encephalopathy.
* Have severe ascites.
* Have hemoglobin concentrations \<9.0 g/dL.
* Have a platelet count of \<50 x 109 cells/L, unless, after consultation with the sponsor, they are considered as acceptable for participation in the study.
* Have total serum bilirubin concentrations \>15 mg/dL (\>257 µmol/L).
* Take medications known to interfere with hepatic metabolism (for example barbiturates, phenothiazines) or known to alter other major organ systems.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes